lilly tirzepatide weight loss orforglipron oral GLP-1 phase 3 trial 37 units of tirzepatide https://investor.lilly.com/news-releases/news-release-details/zepbound-

Thus, expectations for the overall magnitude of effect from a given agent might be modest when treating patients whose baseline A1c is 30 pioglitazone reduced HbA1c levels better than sitagliptin while in individuals with a BMI 90 canagliflozin lowered HbA1c better than sitagliptin while in individuals with an eGFR between 60-90 sitagliptin was more effective (13)

The Pyo 2007 study showed AHK-Cu produces stronger dermal papilla cell proliferation and follicle elongation than GHK-Cu at equivalent concentrations

J Neurosci Off J Soc Neurosci

Un anlisis de datos del mundo real de ms de 9,000 pares coincidentes de pacientes que recibieron semaglutida (Ozempic) y tirzepatida (Mounjaro en dosis para diabetes tipo 2) sugiere que el agonista dual del receptor GIP/GLP-1, tirzepatida, indujo una mayor prdida de peso que su contraparte, el agonista del receptor GLP-1, semaglutida